A. Cancer prevention |
Lifestyle risks |
Hereditary cancer identification and management |
Public education |
B. Identification of early CRC stages |
Screening programs (population coverage) |
Improvement of current tests |
New low-invasive methods (liquid biopsies) |
C. New prognostic and predictive markers necessary to distinguish suitable patients for current treatment |
Patients suitable for neoadjuvant/adjuvant chemotherapy |
High-risk patients where more aggressive approach is applicable |
Predictive markers for targeted therapy |
D. Identification of new molecular targets |
Anti-tumor immunity activation |
Epigenetic changes |
Role of microbiome |
E. Drug development |
New effective molecules against identified targets |
Treatment for larger groups of patients (role of immunotherapy) |
Reduced toxicity and side effects of the treatment |
F. Faster implication of actual knowledge to the clinical practice |
Clinical trials design improvement |
Cost efficiency vs. clinical efficacy acceptable equilibrium |
Suspension of treatment, which has not shown efficacy |